1. P. Agostinis et al., Photodynamic therapy of cancer: an update. CA: a cancer journal for clinicians 61, 250-281 (2011).10.3322/caac.20114.
2. V. S. Chelakkot et al., MEK reduces cancer-specific PpIX accumulation through the RSK-ABCB1 and HIF-1α-FECH axes. Scientific reports 10, 22124-22124 (2020).10.1038/s41598-020-79144-x.
3. D. Ni et al., Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy. Journal of the American Chemical Society 140, 14971-14979 (2018).10.1021/jacs.8b09374.
4. S. Goel et al., Activatable Hybrid Nanotheranostics for Tetramodal Imaging and Synergistic Photothermal/Photodynamic Therapy. Advanced materials (Deerfield Beach, Fla.) 30, (2018).10.1002/adma.201704367.
5. N. Kotagiri, G. P. Sudlow, W. J. Akers, S. Achilefu, Breaking the depth dependency of phototherapy with Cerenkov radiation and low-radiance-responsive nanophotosensitizers. Nature nanotechnology 10, 370-379 (2015).10.1038/nnano.2015.17.
6. X. Ai et al., In vivo covalent cross-linking of photon-converted rare-earth nanostructures for tumour localization and theranostics. Nature communications 7, 10432 (2016).10.1038/ncomms10432.
7. C. Zhang et al., Marriage of scintillator and semiconductor for synchronous radiotherapy and deep photodynamic therapy with diminished oxygen dependence. Angewandte Chemie (International ed. in English) 54, 1770-1774 (2015).10.1002/anie.201408472.
8. D. Duan et al., Activating TiO(2) Nanoparticles: Gallium-68 Serves as a High-Yield Photon Emitter for Cerenkov-Induced Photodynamic Therapy. ACS applied materials & interfaces 10, 5278-5286 (2018).10.1021/acsami.7b17902.
9. A. Kamkaew et al., Cerenkov Radiation Induced Photodynamic Therapy Using Chlorin e6-Loaded Hollow Mesoporous Silica Nanoparticles. ACS applied materials & interfaces 8, 26630-26637 (2016).10.1021/acsami.6b10255.
10. T. M. Shaffer, E. C. Pratt, J. Grimm, Utilizing the power of Cerenkov light with nanotechnology. Nature nanotechnology 12, 106-117 (2017).10.1038/nnano.2016.301.
11. P. Cai et al., A chlorin-lipid nanovesicle nucleus drug for amplified therapeutic effects of lung cancer by internal radiotherapy combined with the Cerenkov radiation-induced photodynamic therapy. Biomater Sci 8, 4841-4851 (2020).10.1039/d0bm00778a.
12. B. Yu et al., A "Missile-Detonation" Strategy to Precisely Supply and Efficiently Amplify Cerenkov Radiation Energy for Cancer Theranostics. Advanced materials (Deerfield Beach, Fla.) 31, e1904894 (2019).10.1002/adma.201904894.
13. Y. Xia et al., Engineering Macrophages for Cancer Immunotherapy and Drug Delivery. Advanced materials (Deerfield Beach, Fla.) 32, e2002054 (2020).10.1002/adma.202002054.
14. J. G. van den Boorn, J. Dassler, C. Coch, M. Schlee, G. Hartmann, Exosomes as nucleic acid nanocarriers. Advanced drug delivery reviews 65, 331-335 (2013).10.1016/j.addr.2012.06.011.
15. S. M. van Dommelen et al., Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. Journal of controlled release : official journal of the Controlled Release Society 161, 635-644 (2012).10.1016/j.jconrel.2011.11.021.
16. T. R. Lunavat et al., RNAi delivery by exosome-mimetic nanovesicles - Implications for targeting c-Myc in cancer. Biomaterials 102, 231-238 (2016).10.1016/j.biomaterials.2016.06.024.
17. R. Molinaro et al., Biomimetic proteolipid vesicles for targeting inflamed tissues. Nat Mater 15, 1037-1046 (2016).10.1038/nmat4644.
18. S. Tan, T. Wu, D. Zhang, Z. Zhang, Cell or cell membrane-based drug delivery systems. Theranostics 5, 863-881 (2015).10.7150/thno.11852.
19. Y. W. Choo et al., M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors. ACS Nano 12, 8977-8993 (2018).10.1021/acsnano.8b02446.
20. H. Fang et al., Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer. Journal of nanobiotechnology 19, 81 (2021).10.1186/s12951-021-00827-2.
21. M. Li et al., Red blood cell membrane-coated upconversion nanoparticles for pretargeted multimodality imaging of triple-negative breast cancer. Biomater Sci 8, 1802-1814 (2020).10.1039/d0bm00029a.
22. H. Fang et al., Ultra-sensitive Nanoprobe Modified with Tumor Cell Membrane for UCL/MRI/PET Multimodality Precise Imaging of Triple-Negative Breast Cancer. Nanomicro Lett 12, 62 (2020).10.1007/s40820-020-0396-4.
23. X. Xu et al., Broaden sources and reduce expenditure: Tumor-specific transformable oxidative stress nanoamplifier enabling economized photodynamic therapy for reinforced oxidation therapy. Theranostics 10, 10513-10530 (2020).10.7150/thno.49731.
24. H. Cheng et al., Mitochondria and plasma membrane dual-targeted chimeric peptide for single-agent synergistic photodynamic therapy. Biomaterials 188, 1-11 (2019).10.1016/j.biomaterials.2018.10.005.
25. S. Y. Li et al., Cancer cell membrane-coated biomimetic platform for tumor targeted photodynamic therapy and hypoxia-amplified bioreductive therapy. Biomaterials 142, 149-161 (2017).10.1016/j.biomaterials.2017.07.026.
26. J. A. Mol, T. J. Visser, Synthesis and some properties of sulfate esters and sulfamates of iodothyronines. Endocrinology 117, 1-7 (1985).10.1210/endo-117-1-1.
27. S. Qi et al., Hypocrellin A-based photodynamic action induces apoptosis in A549 cells through ROS-mediated mitochondrial signaling pathway. Acta Pharm Sin B 9, 279-293 (2019).10.1016/j.apsb.2018.12.004.
28. W. K. Martins et al., Parallel damage in mitochondria and lysosomes is an efficient way to photoinduce cell death. Autophagy 15, 259-279 (2019).10.1080/15548627.2018.1515609.
29. U. Eberlein et al., DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy. J Nucl Med 57, 173-179 (2016).10.2967/jnumed.115.164814.
30. J. Zhang et al., gamma-H2AX responds to DNA damage induced by long-term exposure to combined low-dose-rate neutron and gamma-ray radiation. Mutat Res Genet Toxicol Environ Mutagen 795, 36-40 (2016).10.1016/j.mrgentox.2015.11.004.
31. A. G. McCluskey et al., Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter. J Nucl Med 53, 1146-1154 (2012).10.2967/jnumed.111.095943.
32. M. Gachechiladze, J. Skarda, A. Soltermann, M. Joerger, RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies. Int J Cancer 141, 1286-1294 (2017).10.1002/ijc.30764.
33. Z. Tang, P. Zhao, H. Wang, Y. Liu, W. Bu, Biomedicine Meets Fenton Chemistry. Chemical reviews 121, 1981-2019 (2021).10.1021/acs.chemrev.0c00977.
34. M. Izci, C. Maksoudian, B. B. Manshian, S. J. Soenen, The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors. Chemical reviews 121, 1746-1803 (2021).10.1021/acs.chemrev.0c00779.
35. H. Ding et al., Erythrocyte membrane-coated NIR-triggered biomimetic nanovectors with programmed delivery for photodynamic therapy of cancer. Nanoscale 7, 9806-9815 (2015).10.1039/c5nr02470f.
36. C.-M. J. Hu, R. H. Fang, B. T. Luk, L. Zhang, Nanoparticle-detained toxins for safe and effective vaccination. Nature nanotechnology 8, 933-938 (2013).10.1038/nnano.2013.254.